Form of Underwriting Agreement - Stock Purchase Agreement

This Stock Purchase Agreement (the “Agreement”) is entered into as of , 2011 by and between Free and Clear Equity, Inc., an Indiana corporation (“FACE”), and Monogenesis Corporation, a Delaware corporation (“Monogenesis”).

WHEREAS, Monogenesis is a closed-end investment company with in excess of 1,000 shareholders which was formed to provide a mechanism for companies to become reporting companies under the Securities Act of 1934 through dividend distributions to its shareholders;

WHEREAS, FACE has two classes of stock authorized: Common Shares and Preferred Shares, and will authorize the issuance of the common stock purchase warrants described below;

WHEREAS, as of the date hereof, FACE had authorized 300,000,000 Common Shares, 32,678,400 of which were issued and outstanding, and 15,000,000 Preferred Shares, none of which were issued and outstanding;

WHEREAS, FACE will authorize Common Stock Purchase Warrants (the “Warrants”) to purchase Common Shares of FACE (which Warrants will be exercisable for approximately 120 days and have an exercise price of $2.50 per share);

WHEREAS, prior to the Closing Date (as hereinafter defined), Monogenesis will purchase, and FACE will issue to Monogenesis, 1,402,750 of its Common Shares at a purchase price of $0.01 per share together with 2,986,000 Warrants at a purchase price of $0.001 per Warrant;

WHEREAS, FACE will file a registration statement (the “Registration Statement”) registering 8,169,600 of the Common Shares held by shareholders of FACE, all of the Common Shares and all of the Warrants to be issued to Monogenesis and all of the Common Shares underlying the Warrants pursuant to the Securities Act of 1933, as amended (the “1933 Act”); and

WHEREAS, on the Closing Date, Monogenesis will authorize its transfer agent to dividend to Monogenesis shareholders 250 Common Shares of FACE and 1,000 Warrants of FACE for each share of stock of Monogenesis held;

NOW THEREFORE, in consideration of the mutual covenants and conditions hereinafter set forth, the parties agree as follows:

1.1 Issuance of Securities to Monogenesis. FACE will issue to Monogenesis 1,402,750 Common Shares upon receipt of the purchase price of $0.01 per share and 2,986,000 Warrants (in substantially the form attached hereto as Exhibit 1.1) upon receipt of the purchase price of $0.001 per Warrant.

1.2 Registration Statement. FACE will prepare and file the Registration Statement pursuant to the 1933 Act registering a total of 131,972,350 Common Shares and 3,041,778 Warrants, which constitute 8,169,600 of the 32,678,400 Common Shares held by shareholders of FACE (other than Monogenesis), the 1,402,750 Common Shares and 2,986,000 Warrants to be issued to Monogenesis, the 55,778 Warrants issued to certain consultants and the 122,400,000 Common Shares underlying the Warrants. The shareholders will receive the registered shares as indicated on Schedule 3.2.

2.1 Time and Place. The closing of the transactions contemplated by this Agreement (the “Closing”) shall take place at the place and on such date and at such time within 10 business days after the date on which all of the conditions set forth in Articles VII and VIII to each party’s obligations hereunder have been satisfied or waived, as set forth in a written notice from Monogenesis at least 5 business days prior thereto; or on such other date and at such other time and place as FACE and Monogenesis may mutually agree. The date on which the Closing actually occurs is herein referred to as the “Closing Date.”

2.2 Simultaneous Actions. All proceedings to be taken and all documents to be executed and delivered by the parties at the Closing shall be deemed to have been taken and executed simultaneously and no proceedings shall be deemed taken nor any documents executed or delivered until all have been taken, executed and delivered.

FACE represents and warrants to Monogenesis, all of which representations and warranties shall be true on the Closing Date and shall survive the Closing, that:

3.1 Organization. FACE is a corporation duly organized, validly existing and in good standing under the laws of the State of Indiana and has the power to own its property and carry on its business as it is now being conducted. Copies of the Second Amended and Restated Articles of Incorporation and the Amended and Restated Bylaws of FACE, which have been furnished to Monogenesis, are true and correct copies of said documents including all amendments to the date hereof. The officers and directors of FACE are listed on Schedule 3.1.

3.2 Capitalization. FACE has authorized 300,000,000 Common Shares, par value $.01 per share and 15,000,000 Preferred Shares, par value $.01 per share. Of such shares, including the shares to be issued to Monogenesis, 34,081,150 Common Shares and no Preferred Shares will be issued and outstanding on the Closing Date and have been and will be duly authorized, validly issued, fully paid and nonassessable. A list of all shareholders of FACE and the number and class of shares held by each such shareholder is included on Schedule 3.2. Except for the warrants issued to Monogenesis and the consultants, there is no: (i) outstanding security convertible into or exchangeable for the Common Shares of FACE; (ii) option, warrant, put, call or other right to purchase or subscribe to Common Shares of FACE; or (iii) contract, commitment, agreement, understanding or arrangement of any kind relating to the issuance or

disposition of Common Shares of FACE or the issuance or disposition of any security convertible into Common Shares of FACE. FACE’s records reflect the ownership of all issued and outstanding shares of its stock.

3.3 Authority. FACE has full power to execute and perform this Agreement. The execution and delivery of this Agreement has been duly authorized by all necessary corporate and other actions. Neither the execution nor delivery of this Agreement nor the performance, observation or compliance with its terms and conditions will violate any provision of law, any order of court or other governmental agency, the Second Amended and Restated Articles of Incorporation or Amended and Restated Bylaws of FACE, or any indenture, agreement or other instrument to which FACE is a party, or by which it is bound or by which any of its property is bound. No consent to the performance, observation or compliance with the terms and conditions of this Agreement by FACE is required from any third party.

3.4 Financial Statements. FACE has provided Monogenesis with true and complete copies of the following (collectively, the “Financial Statements”):

(a) the audited balance sheets of FACE as of December 31, 2010, and the related audited statements of earnings and retained earnings and cash flow for the fiscal years then ended, and notes related thereto; and

(b) the unaudited balance sheet (the “Balance Sheet”) of FACE as of March 31, 2011 (the “Balance Sheet Date”) and the related unaudited statement of earnings for the three months then ended, prepared by FACE and accompanied by a certificate in the form of Exhibit 3.4 hereto executed by the persons indicated on said Exhibit.

The Financial Statements either eliminate or clearly disclose all transactions among FACE, the shareholders and their affiliates. Except as otherwise noted in the Financial Statements, the Financial Statements are complete and present fairly the financial position of FACE and the results of its operations as of the dates thereof and for the periods covered thereby in conformity with generally accepted accounting principles applied on a consistent basis.

3.5 Absence of Undisclosed Liabilities. To the knowledge of FACE, at the Balance Sheet Date (i) FACE had no liabilities or obligations of any nature (matured or unmatured, fixed or contingent) which were not provided for or disclosed on the Balance Sheet, (ii) all reserves and allowances provided on the Balance Sheet were adequate for the purposes indicated therein and (iii) there were no loss contingencies (as such term is used in Statement of Financial Accounting Standards No. 5 issued by the Financial Accounting Standards Board (FASB)) which were not adequately provided for in the Balance Sheet.

3.6 Absence of Changes. Since the Balance Sheet Date, FACE’s business has operated in the ordinary course to the extent applicable to a company in the development stage and there has not been (i) any adverse change in its condition (financial or otherwise), assets, liabilities, earnings or business; (ii) any obligation or liability (whether absolute, accrued, contingent or otherwise and whether due or to become due) incurred, or any transaction, contract or commitment entered into, other than items incurred or entered into (as the case may be) in the ordinary course of the business; (iii) any amendment or termination of a material contract,

license, lease, commitment or other agreement to which FACE is a party, except in the ordinary course of business; (iv) any license, sale, transfer, pledge, mortgage or other disposition of any tangible or intangible asset or intellectual property except in the ordinary course of business; (v) any failure to operate its business in the ordinary course of a company in the development stage; or (vi) any dividend or other distribution declared or paid or any change in its outstanding capital stock except as disclosed to Monogenesis.

3.7 Title to Assets. FACE has good and marketable title to all of its assets, free and clear of all mortgages, liens, pledges, charges, security interests, rights of way, options, rights of first refusal, conditions, restrictions or encumbrances of any kind or character, whether or not relating to the extension of credit or the borrowing of money (collectively, “Encumbrances”), except for (i) the Encumbrances disclosed in the Financial Statements and (ii) liens for taxes and governmental charges not yet payable without penalty.

3.8 Litigation. There are no (i) audits, inspections, actions, suits, claims, investigations or legal, administrative or arbitration proceedings pending or threatened against FACE, whether at law or in equity, whether civil or criminal in nature or whether before or by any federal, state, municipal or other governmental department, commission, board, bureau, agency or instrumentality, domestic or foreign, nor, to the knowledge of FACE, does any basis exist therefor or (ii) judgments, decrees, injunctions or orders of any court, governmental department, commission, agency, instrumentality or arbitrator against FACE.

3.9 Compliance; Governmental Authorization. (a) FACE has complied with all federal, state, territorial, local or foreign laws, ordinances, regulations or orders applicable to its business or assets, including, by way of description, and not limitation, matters relating to the environment, anti-competitive practices, discrimination, employment, health and safety, taxes, issuance of securities, customs duties and requirements and foreign practices. FACE has all federal, state, territorial, local and foreign governmental licenses and permits necessary in the conduct of its business as presently conducted (noting that operations have not yet began) and no violations are outstanding or uncured with respect to any such licenses or permits and no proceeding is pending or threatened to revoke or limit any of them. Such licenses, consents and permits shall not be affected in any respect by the transactions contemplated hereby.

(b) As used in this Agreement, “Hazardous Substance” shall mean and include all hazardous or toxic substances, wastes or materials, any pollutants or contaminants (including, without limitation, all oil and petroleum of any kind and in any form, asbestos and raw materials which include hazardous constituents), or any other similar substances, or materials which are included under or regulated by any applicable local, state, federal or foreign law, rule or regulation pertaining to environmental regulation, contamination, clean-up or disclosure, including, without limitation, the Clean Air Act, the Federal Water Pollution Control Act, the Comprehensive Environmental Response, Compensation and Liability Act of 1980, the Superfund Amendments and Reauthorization Act of 1986, the Resource Conservation and Recovery Act of 1976, the Toxic Substances Control Act, the Federal Insecticide, Fungicide and Rodenticide Act, the Occupational Safety and Health Act, the Emergency Planning and Community Right-to-Know Act of 1986, and all comparable applicable state or local laws, orders and regulations, as any of the foregoing has heretofore been amended.

(c) FACE hereby warrants to Monogenesis that FACE and the supervisory employees, officers and directors of FACE have no knowledge of the presence, storage, disposition, generation, treatment, release or discharge of any Hazardous Substance on, under or about the assets owned by FACE or the land and buildings on and in which FACE currently conducts or has conducted its operations except in accordance with applicable laws.

3.10 Labor Relations; Employees. FACE is in compliance with all applicable federal, state, territorial, local and foreign laws and regulations respecting labor, employment and employment practices, terms and conditions of employment and wages and hours. There is no unfair labor practice complaint against FACE pending before any state, local or foreign agency. There is no labor strike, dispute, slowdown, stoppage or organizational effort or similar activity actually pending or, to the knowledge of FACE, threatened involving FACE; no representation question exists respecting the employees of FACE; and no collective bargaining agreement presently covers any employees of FACE, nor is any currently being negotiated.

3.11 Employee Benefit Plans. FACE currently does not have any “employee pension benefit” plans (as defined in Section 3(2) of the Employee Retirement Income Security Act of 1974, as amended (“ERISA”)), any “employee welfare benefit” plans (as defined in Section 3(1) of ERISA) or any other qualified or non-qualified plans, programs or letters of commitment promising current or future benefits or deferred compensation.

3.12 Accounts and Notes Receivable. Except as otherwise reflected in the Financial Statements, all unpaid accounts and notes receivable outstanding at the date hereof constitute, and those outstanding at the Closing Date will constitute, valid and enforceable claims arising in bona fide transactions in the ordinary course of business, except as enforceability is limited by applicable bankruptcy, reorganization, insolvency, moratorium, fraudulent conveyance or similar laws affecting the enforcement of creditors rights generally.

3.13 Tax Matters. For purposes of this Agreement, the term “Taxes” means all taxes of any kind or nature, including but not limited to federal, state, local and foreign income taxes, withholding taxes, branch profit taxes, gross receipts taxes, franchise taxes, sales and use taxes, business and occupation taxes, property taxes, VAT, custom duties or imposts, stamp taxes, excise taxes, payroll taxes, intangible taxes and capital taxes and any penalties or interest thereon. FACE has filed within the time and in the manner prescribed by law all tax returns and reports required to be filed by it under the laws of the United States and each state or other jurisdiction in which it conducts business activities requiring the filing of tax returns or reports. FACE has paid or set up adequate reserves in the Balance Sheet in respect of all Taxes. There are no tax liens, whether imposed by the United States, any state, local, foreign or other taxing authority, outstanding against FACE or its assets. All Taxes and assessments that FACE is required to withhold or to collect have been duly withheld or collected and all withholdings and collections have either been duly and timely paid over to the appropriate governmental authorities or are, together with the payments due or to become due in connection therewith, duly reflected on the Balance Sheet in accordance with generally accepted accounting principles.

3.14 Books and Records. The books of account and other corporate financial records of FACE are in all material respects complete and correct, have been maintained in accordance with good business practices and matters contained therein are appropriately and accurately

reflected in the Financial Statements. The corporate record books of FACE contain true and complete copies of the minutes of all meetings of its shareholders and directors.

3.15 Disclosure. Neither this Agreement (including the Schedules and Exhibits attached hereto) nor any other document, certificate or statement furnished to Monogenesis by or on behalf of FACE in connection with the transactions contemplated hereby, when considered in the aggregate with all other such documents, certificates or statements, contains any untrue statement of a material fact or omits to state a material fact necessary in order to make the statements contained herein and therein not misleading.

Monogenesis represents and warrants, all of which representations and warranties shall be true on the Closing Date and shall survive the Closing, that:

4.1 Organization. Monogenesis is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware and has the corporate power to carry on its business as it is now being conducted.

4.2 Authority. Monogenesis has the full power to execute and perform this Agreement. The execution and delivery of this Agreement has been duly authorized by all necessary corporate and other actions. Neither the execution nor delivery of this Agreement nor the performance, observance or compliance with its terms and conditions will violate any provision of law, any order of court or other governmental agency, the Certificate of Incorporation or Bylaws of Monogenesis or any indenture, agreement or other instrument to which Monogenesis is a party, or by which it is bound. No consent to the performance, observation or compliance with the terms and conditions of this Agreement by Monogenesis is required from any third party.

5.1 Conduct of Business Until Closing Date. Except as permitted or required hereby or as Monogenesis may otherwise consent in writing, between the date hereof and the Closing Date, FACE shall neither declare, set aside, pay or make any dividend or other distribution or payment on or in respect of shares of its stock, nor directly or indirectly redeem, retire, purchase or otherwise acquire any of its stock.

5.2 Access to Properties and Records. FACE shall give to Monogenesis and its representatives reasonable access hours to FACE’s properties, personnel, books, tax returns, contracts, commitments and records and the right to make copies thereof. FACE shall furnish to Monogenesis and such representatives all such additional documents and financial and other information as Monogenesis or its representatives may from time to time reasonably request and

permit Monogenesis and such representatives to examine all records and working papers relating to the preparation, review and audits of FACE’s financial statements and tax returns.

5.3 Advice of Changes. Between the date hereof and the Closing Date, FACE shall advise Monogenesis promptly in writing of any fact of which FACE becomes aware, which, if known at the date hereof, would have been required to be set forth or disclosed in or pursuant to this Agreement.

5.4 Conduct. Except as permitted or required hereby or as FACE may notify Monogenesis in writing, FACE shall not enter into any transaction, take any action, or fail to take any action, which would result in any of the representations and warranties contained in this Agreement or in any Schedule or Exhibit hereto not being true and correct at and as of the time immediately after such transaction has been entered into or such event has occurred and on the Closing Date.

5.5 Approvals, Consents. FACE will obtain in writing prior to the Closing Date all approvals, consents and waivers, required to be obtained in order to effectuate the transactions contemplated hereby, and shall deliver to Monogenesis copies thereof, reasonably satisfactory in form and substance to Monogenesis.

6.1 Confidentiality; Return of Documents. Unless and until the transactions contemplated by this Agreement are consummated, Monogenesis shall keep in confidence all proprietary and financial information of FACE, and shall not, except to the extent required by law or to the extent any such information is otherwise publicly available, without the prior written consent of FACE, reveal any such financial or proprietary information to any third party other than securities regulatory authorities in connection with the Registration Statement or counsel, accountants or experts retained by Monogenesis who shall be bound by the same restrictions. If the transactions contemplated by this Agreement are not consummated, at FACE’s request, Monogenesis shall return to FACE all documents supplied to Monogenesis pursuant to the provisions of this Agreement.

The obligation of Monogenesis to perform as provided in this Agreement is subject to the satisfaction at or prior to the Closing Date of the following conditions unless waived by Monogenesis in its sole discretion:

7.1 Accuracy of Representations and Warranties. The representations and warranties of FACE contained in this Agreement and in any Schedule or Exhibit hereto shall be true and accurate in all material respects on and as of the Closing Date, with the same force and effect as if made on the Closing Date, except as affected by transactions required or permitted hereby, and except that any such representation or warranty made as of a specified date (other

than the date of this Agreement) shall have been true and accurate in all material respects on and as of such date.

7.2 Performance of Agreements. FACE shall have performed and complied with all covenants, obligations and agreements to be performed or complied with, on or before the Closing Date pursuant to this Agreement or any Schedule or Exhibit hereto.

7.3 Officer’s Certificates. Monogenesis shall have received an accurate certificate of a duly authorized officer of FACE dated the Closing Date, satisfactory in form and substance to Monogenesis, certifying the fulfillment of the matters specified in Sections 7.1 and 7.2.

7.4 Secretary’s Certificate. Monogenesis shall have received an accurate certificate of the Secretary of FACE, dated the Closing Date, satisfactory in form and substance to Monogenesis, with respect to the resolutions adopted by the Board of Directors of FACE approving this Agreement and the transactions contemplated hereby.

7.5 Consents, Authorizations. All consents, authorizations, orders or approvals of, and filings or registrations with and the expiration of all waiting periods imposed by, any third party, including, without limitation, any federal, state or local commission, board or other regulatory body, lender, lessor, licensor or supplier which are required for or in connection with the execution and delivery of this Agreement by FACE and the consummation of the transactions contemplated hereby shall have been duly obtained or made and shall be in full force and effect.

7.6 Legislation. No federal, state or local statute, rule or regulation shall have been enacted after the date of this Agreement which prohibits, restricts, delays or materially adversely affects the business or the proposed business of FACE or the consummation of the transactions contemplated by this Agreement or any of the conditions to the consummation of such transactions. No temporary restraining order or injunction shall be in effect, or threatened by a governmental agency, restraining the consummation of the transactions contemplated hereby.

7.7 Issuance, Registration and Dividend of Shares and Warrants. FACE shall have taken all steps necessary to issue the shares and Warrants in accordance with this Agreement. Monogenesis shall have resolved to dividend to each of its shareholders 250 Common Shares and 1,000 Warrants of FACE to be issued to Monogenesis for each share of stock of Monogenesis held by such shareholder. The Registration Statement shall have been filed registering 8,169,600 of the Common Shares held by shareholders of FACE, all of the Common Shares to be issued to Monogenesis, all of the Warrants and all of the Common Shares underlying the Warrants, and such Registration Statement shall have become effective.

7.8 Financial Statements. Monogenesis shall have received the unaudited balance sheets of FACE as of the quarter-end immediately preceding the Closing Date (or the prior quarter-end if the Closing occurs within forty-five days of the end of a quarter), and the related unaudited statements of earnings, retained earnings and cash flows for the portion then ended, presented on a comparative basis with financial statements of the same portion of the preceding fiscal year, prepared by FACE and accompanied by a certificate in the form of Exhibit 3.4 attached hereto executed by the persons indicated on said Exhibit. Such statements shall not

differ from those for the comparable period of the preceding fiscal year in any materially adverse respect.

The obligation of FACE to perform its obligations under this Agreement is subject to the satisfaction at or prior to the Closing Date of the following conditions unless waived by FACE in its sole discretion:

8.1 Accuracy of Representations and Warranties. The representations and warranties of Monogenesis contained in this Agreement or in any Schedule or Exhibit hereto shall be true and accurate in all material respects on and as of the Closing Date, with the same force and effect as if made on the Closing Date, except as affected by transactions required or permitted hereby, and except that any such representation or warranty made as of a specified date (other than the date of this Agreement), shall have been true and accurate in all material respects on and as of such date.

8.2 Performance of Agreements. Monogenesis shall have performed and complied in all material respects with all covenants, obligations and agreements to be performed or complied with by it on or before the Closing Date pursuant to this Agreement or any Schedule or Exhibit hereto.

8.3 Consents, Authorizations. All consents, authorizations, orders or approvals of, and filings or registrations with, and the expiration of all waiting periods imposed by any third party, including without limitation, any federal, state or local commission, board or other regulatory body which are required for or in connection with the execution and delivery by Monogenesis of this Agreement and the consummation by Monogenesis of the transactions contemplated hereby shall have been obtained or made and shall be in full force and effect.

8.4 Legislation. No federal, state or local statute, rule or regulation shall have been enacted after the date of this Agreement which prohibits, restricts, delays or materially adversely affects the consummation of the transactions contemplated by this Agreement or any of the conditions to the consummation of such transactions. No temporary restraining order or injunction shall be in effect, or threatened by a governmental agency, restraining the consummation of the transactions contemplated hereby.

8.5 Issuance, Registration and Dividend of Shares and Warrants. FACE shall have taken all steps necessary to issue the shares and Warrants to Monogenesis in accordance with this Agreement. Monogenesis shall have resolved to dividend to each of its shareholders 250 Common Shares and 1,000 Warrants of FACE to be issued to Monogenesis for each share of stock of Monogenesis held by such shareholder. The Registration Statement shall have been filed registering 8,169,600 of the Common Shares held by the shareholders of FACE, all of the Common Shares to be issued to Monogenesis, all of the Warrants and all of the Common Shares underlying the Warrants, and such Registration Statement shall have be become effective.

9.1 Termination. This Agreement may be terminated at any time prior to the Closing Date:

(a) by Monogenesis, if there has been a violation or breach by FACE of any material agreement, representation or warranty contained in this Agreement and such violation or breach has not been waived by Monogenesis, or, with respect to a violation or breach of an agreement, cured within 10 business days after the receipt of written notice thereof; or

(b) by FACE, if there has been a violation or breach by Monogenesis of any material agreement, representation or warranty of Monogenesis contained in this Agreement and such violation or breach has not been waived by FACE or, with respect to a violation or breach of an agreement, cured within 10 business days after the receipt of written notice thereof.

In the event of termination of this Agreement and abandonment of the transactions contemplated hereby pursuant to this Section 9.1, written notice thereof shall immediately be given to the other party and this Agreement shall terminate and the transactions contemplated hereby shall be abandoned, without further action by any of the parties hereto. The provisions of Sections 6.1, 10.1 and 10.2 shall survive any such termination.

10.1 Indemnification. (a) FACE shall indemnify, defend and save Monogenesis harmless from, against, for and in respect of the following: (i) any damages, losses, obligations, liabilities, claims, actions or causes of action sustained or suffered by Monogenesis and arising from a breach of any representation, warranty, covenant or agreement of FACE contained in or made pursuant to this Agreement (including the Schedules and Exhibits attached hereto), or in any certificate, instrument or agreement delivered by FACE pursuant hereto or in connection with the transactions contemplated hereby; and (ii) all reasonable costs and expenses (including, without limitation, reasonable fees and expenses of attorneys, accountants and other professionals) incurred by Monogenesis in connection with any action, suit, proceeding, demand, investigation, assessment or judgment incident to any of the matters indemnified against under this Section 10.1(a). Monogenesis shall not bring a claim, demand, suit or cause of action against FACE under or pursuant to this Section 10.1(a) with respect to the representations and warranties set forth herein unless Monogenesis has first given FACE written notice, with reasonable specificity, of the existence of any such claim, demand, suit or cause of action under this Agreement. Upon the giving of such written notice as aforesaid, Monogenesis shall have the right, in addition to all other remedies available to it, to commence legal proceedings for the enforcement of its rights under this Agreement. Monogenesis, at its option and with at least two days advance notice to the affected party, may recover any such liability by set off against payments otherwise required to be made by Monogenesis to such party pursuant to any agreement between Monogenesis and such party.

(b) Monogenesis shall indemnify, defend and save FACE harmless from, against, for and in respect of the following: (i) any damages, losses, obligations, liabilities, claims, actions or causes of action sustained or suffered by FACE and arising from a breach of any representation, warranty, covenant or agreement of Monogenesis contained in or made pursuant to this Agreement or in any certificate, instrument or agreement delivered by it pursuant hereto or in connection with the transactions contemplated hereby; and (ii) all reasonable costs and expenses (including, without limitation, reasonable fees and expenses of attorneys, accountants and other professionals) incurred by FACE in connection with any action, suit, proceeding, demand, investigation, assessment or judgment incident to any of the matters indemnified against under this Section 10.1(b). FACE shall not bring a claim, demand, suit or cause of action against Monogenesis under or pursuant to this Section 10.1(b) unless FACE has first given Monogenesis written notice, with reasonable specificity, of the existence of any such claim, demand, suit or cause of action under this Agreement. Upon the giving of such written notice as aforesaid, such party shall have the right, in addition to all other remedies available to it, to commence legal proceedings for the enforcement of its rights under this Agreement.

10.2 Third Party Claims. With respect to claims resulting from the assertion of liability by third parties, the obligations and liabilities of the party responsible for indemnification (the “Indemnifying Party”) hereunder with respect to indemnification claims by the party entitled to indemnity (the “Indemnified Party”) shall be subject to the following terms and conditions: (i) the Indemnified Party shall give prompt written notice to the Indemnifying Party of any assertion of liability by a third party which might give rise to a claim by the Indemnified Party against the Indemnifying Party based on the indemnity agreements contained in Section 10.1 hereof, stating the nature and basis of said assertion and the amount thereof, to the extent known; and (ii) the Indemnifying Party shall not make any settlement of any claims without the written consent of the Indemnified Party; provided, however, that if an Indemnified Party does not consent to a settlement proposed by the Indemnifying Party and accepted by the adverse third party, the liability of the Indemnifying Party shall be limited to the amount that would have been paid in such settlement.

10.3 Remedies Cumulative. The remedies provided for in this Article X shall be cumulative and shall not preclude assertion by the Indemnified Party of any other rights or the seeking of any other remedies against the Indemnifying Party.

10.4 Recoveries. In the event an Indemnified Party subsequently receives payment (including without limitation proceeds of insurance and payments on accounts receivable) with respect to a matter for which it has been fully indemnified by the Indemnifying Party, the Indemnified Party shall promptly pay the amount of such payment up to the indemnification received, to the Indemnifying Party.

11.1 Expenses; Transfer Taxes. All fees, costs and expenses incurred by FACE or Monogenesis in connection with, relating to or arising out of the preparation, execution, delivery and performance of this Agreement and the consummation of the transactions contemplated hereby, including, without limitation, fees of the transfer agent and legal and accounting fees and

expenses relating to the preparation and filing of the Registration Statement, shall be borne by FACE.

11.2 Binding Effect. This Agreement shall become binding and effective when executed by the parties hereto. This Agreement shall not be assignable by any party without the prior written consent of the other parties, except that without relieving Monogenesis of any of its obligations under this Agreement, Monogenesis may assign this Agreement to any of its affiliates. Subject to the foregoing, this Agreement shall be binding upon, inure to the benefit of, and be enforceable by, the respective successors, heirs, legal representatives and assigns of the parties hereto. This Agreement constitutes an agreement among the parties hereto and none of the agreements, covenants, representations or warranties contained herein shall be for the benefit of any third party not a party to this Agreement.

11.3 Entire Agreement; Amendments. This Agreement (including the Schedules and Exhibits attached hereto) contains the entire understanding of the parties with respect to its subject matter. This Agreement supersedes all prior agreements and understandings between the parties with respect to the subject matter hereof. This Agreement may be amended only by a written instrument duly executed by the parties, and any condition to a party’s obligations hereunder may only be waived in writing by such party.

11.4 Headings. The article and section headings contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement.

11.5 Notices. All notices, claims, certificates, requests, demands and other communications hereunder shall be in writing and shall be deemed given if delivered personally, if mailed (by registered or certified mail, return receipt requested and postage prepaid), if sent by reputable overnight courier service for next business day delivery, or if sent by facsimile transmission, as follows:

or to such other address as the party to whom notice is to be given may have furnished to the other party in writing in accordance herewith. Any such communication shall be effective on the date of receipt (or, if received on a non-business day, on the first business day after the date of receipt).

11.6 Publicity. The parties agree that, except as otherwise required by law, the issuance of any reports, statements or releases pertaining to this Agreement or the transactions contemplated hereby is subject to mutual consent.

11.7 Governing Law. This Agreement shall be governed by and construed in accordance with the internal laws of the State of Delaware (without giving effect to its laws regarding conflicts of law).

11.8 Waivers. Any provision of this Agreement may be waived only by a written instrument executed by the party to be charged with such waiver. The waiver by any party hereto of a breach of any provision of this Agreement shall not operate or be construed as a waiver of any subsequent breach.

11.9 Defined Terms. Throughout this Agreement various terms have been defined by being enclosed in quotation marks, usually in parentheses, and used with their initial letters capitalized. Unless the context otherwise requires, such defined terms shall have their designated meaning whenever used in this Agreement or any attached schedules.

11.10 Fees. If there is any litigation between the parties related to this Agreement or the transactions contemplated by this Agreement, the prevailing party shall be entitled to recover all reasonable costs and expenses (including, without limitation, reasonable fees and expenses of attorneys, accountants and other professionals).

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed and delivered on the date first above written.


Free and Clear Equity, Inc.

By:

Title:

Monogenesis Corporation

By:

Title:

The undersigned, President of Free and Clear Equity, Inc. (the “Corporation”), certifies that:

1. The balance sheet of the Corporation as of and the income statement of the Corporation for the period ending on (collectively, the “Financial Statements”), all as attached hereto and provided in connection with the Stock Purchase Agreement between the Corporation and Monogenesis Corporation dated , 2011, are complete and present fairly the financial position of the Corporation.

2. The undersigned is not aware of any matters which are not reflected on such Financial Statements or which would make such Financial Statements misleading in any manner.


By:
		Chance W. Bunger


if to FACE to:		Free and Clear Equity, Inc. 201 N. Illinois Street 16^th Floor, South Tower Indianapolis, Indiana 46204 Attn.: Jeffrey J. Jinks Telephone: (317) 610-3252 Facsimile: (317) 535-1717

if to Monogenesis to:		Monogenesis Corporation Drawer 88, Walker Creek Road Walker, West Virginia 26180-9948 Telephone: (304) 485-5000


Name		Office
Chance W. Bunger		President, Chief Executive Officer, Director
Thomas G. Ferkinhoff		Chief Financial Officer, Treasurer, Director
Jeffrey J. Jinks		Secretary, Director


Name	Number of Common Shares		Number of Registered Common Shares
FACE of Indiana, LLC		20,424,000		5,106,000
Jeffrey J. Jinks		10,212,000		2,553,000
Chance W. Bunger		2,042,400		510,600


ARTICLE I SECURITIES		1
1.1	Issuance of Securities to Monogenesis	1
1.2	Registration Statement	2

ARTICLE II CLOSING		2
2.1	Time and Place	2
2.2	Simultaneous Actions	2

ARTICLE III REPRESENTATIONS AND WARRANTIES OF FACE		2
3.1	Organization	2
3.2	Capitalization	2
3.3	Authority	3
3.4	Financial Statements	3
3.5	Absence of Undisclosed Liabilities	3
3.6	Absence of Changes	3
3.7	Title to Assets	4
3.8	Litigation	4
3.9	Compliance; Governmental Authorization	4
3.10	Labor Relations; Employees	5
3.11	Employee Benefit Plans	5
3.12	Accounts and Notes Receivable	5
3.13	Tax Matters	5
3.14	Books and Records	5
3.15	Disclosure	6

ARTICLE IV REPRESENTATIONS AND WARRANTIES OF MONOGENESIS		6
4.1	Organization	6
4.2	Authority	6
4.3	Shareholders	6

ARTICLE V COVENANTS OF FACE		6
5.1	Conduct of Business Until Closing Date	6
5.2	Access to Properties and Records	6
5.3	Advice of Changes	7
5.4	Conduct	7
5.5	Approvals, Consents	7

ARTICLE VI COVENANTS OF MONOGENESIS		7
6.1	Confidentiality; Return of Documents	7

ARTICLE VII CONDITIONS TO OBLIGATIONS OF MONOGENESIS		7
7.1	Accuracy of Representations and Warranties	7
7.2	Performance of Agreements	8
7.3	Officer’s Certificates	8


7.4	Secretary’s Certificate	8
7.5	Consents, Authorizations	8
7.6	Legislation	8
7.7	Issuance, Registration and Dividend of Shares and Warrants	8
7.8	Financial Statements	8

ARTICLE VIII CONDITIONS TO OBLIGATIONS OF FACE		9
8.1	Accuracy of Representations and Warranties	9
8.2	Performance of Agreements	9
8.3	Consents, Authorizations	9
8.4	Legislation	9
8.5	Issuance, Registration and Dividend of Shares and Warrants	9

ARTICLE IX TERMINATION		10
9.1	Termination	10

ARTICLE X INDEMNIFICATION		10
10.1	Indemnification	10
10.2	Third Party Claims	11
10.3	Remedies Cumulative	11
10.4	Recoveries	11

ARTICLE XI MISCELLANEOUS		11
11.1	Expenses; Transfer Taxes	11
11.2	Binding Effect	12
11.3	Entire Agreement; Amendments	12
11.4	Headings	12
11.5	Notices	12
11.6	Publicity	13
11.7	Governing Law	13
11.8	Waivers	13
11.9	Defined Terms	13
11.10	Fees	13